trans-AUCB (t-AUCB) is a potent, orally active, and selective soluble epoxide hydrolase (sEH) inhibitor with IC50s of 1.3 nM (hsEH), 8 nM (mouse sEH), and 8 nM (rat sEH). It exhibits anti-glioma activity.
- It suppresses U251 and U87 cell growth in a dose-dependent manner.
- It induces cell-cycle G0/G1 phase arrest in U251 and U87 cells.
- It increases phosphorylation levels of p65, peaking at 30 minutes and lasting at least 2 hours.
- It suppresses U251 and U87 cell growth by activating NF-κB-p65.
- It efficiently inhibits sEH activities in human glioblastoma (U251, U87) and hepatocellular carcinoma (HepG2) cell lines.
- In vivo, it ameliorates LPS-induced hypotension.
- It demonstrates pharmacokinetic properties with varying t1/2 and Cmax values depending on administration route and dosage.